BL-M07D1-ST-101: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Condition: HER2 Expressing Solid Tumors
Sponsor: SystImmune Inc.
Full Title
BL-M07D1-ST-101: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects with HER2 Expressing Advanced Malignant Solid Tumors
Study Treatment
HER2 targeting antibody-drug conjugate BL-M07D1
Eligibility/Info
HER2 1+ to 3+ by IHC or Positive by ISH or ERBB2 amplified by NGS advanced/metastatic solid tumor
- Cohort 1: Endometrial cancer
- Cohort 2: Cervical cancer
- Cohort 3: Ovarian cancer
- Cohort 4: Urothelial cancer
- Cohort 5: Biliary tract cancer
- Cohort 6: Breast cancer
- Cohort 7: Lung cancer
- Cohort 8: Gastric, esophageal, or gastroesophageal junction cancer
Treated with at least 2 prior lines of therapy and is refractory to standard of care therapies with no standard treatment available
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
